Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reparixin in Acute Respiratory Distress Syndrome (RESPIRATIO)
NCT05496868Phase 2Completed
- Sponsor
- Dompé
- Start
- Dec 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of reparixin in acute respiratory distress syndrome (ARDS), sponsored by Dompé. Started Dec 2022; status: completed.
02
Drugs
reparixin
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05496868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05496868.